Arvind Sahu

List of Publications by Year
in descending order

70 papers	3,119 citations	159585 30 h-index	161849 54 g-index
80 all docs	80 docs citations	80 times ranked	2749 citing authors

#	Article	IF	Citations
1	From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors. Clinical Immunology, 2022, 235, 108785.	3.2	30
2	Virus-Encoded Complement Regulators: Current Status. Viruses, 2021, 13, 208.	3.3	5
3	Role of Electrostatic Hotspots in the Selectivity of Complement Control Proteins Toward Human and Bovine Complement Inhibition. Frontiers in Molecular Biosciences, 2021, 8, 618068.	3.5	1
4	Differential expression of complement receptors CR1/2 and CR4 by murine M1 and M2 macrophages. Molecular Immunology, 2021, 137, 75-83.	2.2	2
5	The imitation game: a viral strategy to subvert the complement system. FEBS Letters, 2020, 594, 2518-2542.	2.8	13
6	Spatially conserved motifs in complement control protein domains determine functionality in regulators of complement activation-family proteins. Communications Biology, 2019, 2, 290.	4.4	11
7	Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database. Frontiers in Immunology, 2019, 10, 1282.	4.8	38
8	Molecular engineering of an efficient four-domain DAF-MCP chimera reveals the presence of functional modularity in RCA proteins. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9953-9958.	7.1	7
9	Structural basis of hypoxic gene regulation by the Rv0081 transcription factor of <i>MycobacteriumÂtuberculosis</i>. FEBS Letters, 2019, 593, 982-995.	2.8	8
10	Characterization of genetic predisposition and autoantibody profile in atypical haemolyticâ€“uraemic syndrome. Immunology, 2018, 154, 663-672.	4.4	20
11	Fungal melanin stimulates surfactant protein Dâ€“mediated opsonization of and host immune response to Aspergillus fumigatus spores. Journal of Biological Chemistry, 2018, 293, 4901-4912.	3.4	36
12	Aspergillus fumigatus conidial metalloprotease Mep1p cleaves host complement proteins. Journal of Biological Chemistry, 2018, 293, 15538-15555.	3.4	34
13	Selective recruitment of nucleoporins on vaccinia virus factories and the role of Nup358 in viral infection. Virology, 2017, 512, 151-160.	2.4	13
14	Complement Evasion Strategies of Viruses: An Overview. Frontiers in Microbiology, 2017, 8, 1117.	3.5	117
15	Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I. Journal of Virology, 2017, 91, .	3.4	7
16	Synergy between the classical and alternative pathways of complement is essential for conferring effective protection against the pandemic influenza A(H1N1) 2009 virus infection. PLoS Pathogens, 2017, 13, e1006248.	4.7	38
17	Domain swapping reveals functional modularity present in the decay-accelerating factor (CD55). Immunobiology, 2016, 221, 1181-1182.	1.9	1
18	Mutational analysis of Kaposica reveals that bridging of MG2 and CUB domains of target protein is crucial for the cofactor activity of RCA proteins. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12794-12799.	7.1	12

#	Article	IF	Citations
19	Viral regulators of complement activation: Structure, function and evolution. Molecular Immunology, 2014, 61, 89-99.	2.2	31
20	Dissection of Functional Sites in Herpesvirus Saimiri Complement Control Protein Homolog. Journal of Virology, 2013, 87, 282-295.	3.4	10
21	Species Selectivity in Poxviral Complement Regulators Is Dictated by the Charge Reversal in the Central Complement Control Protein Modules. Journal of Immunology, 2012, 189, 1431-1439.	0.8	13
22	Species selectivity in poxviral complement regulators is dictated primarily by the charge reversal in the central complement control protein modules. Immunobiology, 2012, 217, 1217.	1.9	0
23	Disabling complement regulatory activities of vaccinia virus complement control protein reduces vaccinia virus pathogenicity. Vaccine, 2011, 29, 7435-7443.	3.8	14
24	Identification of a novel complement inhibitor Complin that inhibits activation of factor B and C2. Molecular Immunology, 2010, 47, 2240-2241.	2.2	0
25	Influence of Electrostatics on the Complement Regulatory Functions of Kaposica, the Complement Inhibitor of Kaposiâ€™s Sarcoma-Associated Herpesvirus. Journal of Immunology, 2010, 184, 1956-1967.	0.8	33
26	Identification of Complin, a Novel Complement Inhibitor that Targets Complement Proteins Factor B and C2. Journal of Immunology, 2010, 184, 7116-7124.	0.8	5
27	Domain Swapping Reveals Complement Control Protein Modules Critical for Imparting Cofactor and Decay-Accelerating Activities in Vaccinia Virus Complement Control Protein. Journal of Immunology, 2010, 185, 6128-6137.	0.8	11
28	Virusâ€“complement interactions: an assiduous struggle for dominance. Future Virology, 2010, 5, 709-730.	1.8	12
29	Mapping of Functional Domains in Herpesvirus Saimiri Complement Control Protein Homolog: Complement Control Protein Domain 2 Is the Smallest Structural Unit Displaying Cofactor and Decay-Accelerating Activities. Journal of Virology, 2009, 83, 10299-10304.	3.4	8
30	Identification of Hot Spots in the Variola Virus Complement Inhibitor (SPICE) for Human Complement Regulation. Journal of Virology, 2008, 82, 3283-3294.	3.4	36
31	Viral complement regulators: the expert mimicking swindlers. Indian Journal of Biochemistry and Biophysics, 2007, 44, 331-43.	0.0	12
32	Compstatin inhibits complement activation by binding to the Î²-chain of complement factor 3. Molecular Immunology, 2006, 43, 2023-2029.	2.2	25
33	Functional Characterization of the Complement Control Protein Homolog of Herpesvirus Saimiri. Journal of Biological Chemistry, 2006, 281, 23119-23128.	3.4	25
34	Identification of Complement Regulatory Domains in Vaccinia Virus Complement Control Protein. Journal of Virology, 2005, 79, 12382-12393.	3.4	40
35	Identification of Functional Domains in Kaposica, the Complement Control Protein Homolog of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8). Journal of Virology, 2005, 79, 5850-5856.	3.4	31
36	Kinetic Analysis of the Interactions between Vaccinia Virus Complement Control Protein and Human Complement Proteins C3b and C4b. Journal of Virology, 2004, 78, 9446-9457.	3.4	37

#	Article	IF	Citations
37	Viral mimicry of the complement system. Journal of Biosciences, 2003, 28, 249-264.	1.1	76
38	Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Molecular Immunology, 2003, 39, 557-566.	2.2	81
39	Herpes and pox viral complement control proteins: â€˜the mask of selfâ€™. Trends in Immunology, 2003, 24, 500-507.	6.8	38
40	Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Open Reading Frame 4 Protein (Kaposica) Is a Functional Homolog of Complement Control Proteins. Journal of Virology, 2003, 77, 3878-3881.	3.4	60
41	Studies of Structure-Activity Relations of Complement Inhibitor Compstatin. Journal of Immunology, 2003, 171, 1881-1890.	0.8	39
42	The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR. Journal of Biological Chemistry, 2002, 277, 14942-14953.	3.4	50
43	Cloning and purification of the rainbow trout fifth component of complement (C5). Developmental and Comparative Immunology, 2001, 25, 419-430.	2.3	54
44	Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunological Reviews, 2001, 180, 35-48.	6.0	449
45	Kinetic Analysis of the Interactions of Complement Receptor 2 (CR2, CD21) with Its Ligands C3d, iC3b, and the EBV Glycoprotein gp350/220. Journal of Immunology, 2001, 167, 1490-1499.	0.8	72
46	Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology, 2000, 49, 133-148.	2.0	147
47	Binding Kinetics, Structure-Activity Relationship, and Biotransformation of the Complement Inhibitor Compstatin. Journal of Immunology, 2000, 165, 2491-2499.	0.8	105
48	Inhibition of Heparin/Protamine Complex-Induced Complement Activation by Compstatin in Baboons. Clinical Immunology, 2000, 96, 212-221.	3.2	68
49	In Vivo Role of Complement-Interacting Domains of Herpes Simplex Virus Type 1 Glycoprotein Gc. Journal of Experimental Medicine, 1999, 190, 1637-1646.	8.5	108
50	Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 628-633.	7.1	149
51	Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation, 1999, 6, 52-65.	2.8	90
52	Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. Biochemical Pharmacology, 1999, 57, 1439-1446.	4.4	82
53	Prolongation of ex vivoâ€"perfused pig xenograft survival by the complement inhibitor compstatin. Transplantation Proceedings, 1999, 31, 934-935.	0.6	26
54	Structure, functions, and evolution of the third complement component and viral molecular mimicry. Immunologic Research, 1998, 17, 109-121.	2.9	27

#	Article	IF	Citations
55	Solution structure of Compstatin, a potent complement inhibitor. Protein Science, 1998, 7, 619-627.	7.6	87
56	Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation. Blood, 1998, 92, 1661-1667.	1.4	133
57	The Chemistry and Biology of C3, C4 and C5. , 1998, , 83-118.		42
58	Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation. Blood, 1998, 92, 1661-1667.	1.4	6
59	Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3. Biochemical Pharmacology, 1996, 51, 797-804.	4.4	26
60	Multiple forms of complement C3 in trout that differ in binding to complement activators.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 8546-8551.	7.1	141
61	Tyrosine is a potential site for covalent attachment of activated complement component C3. Molecular Immunology, 1995, 32, 711-716.	2.2	27
62	Antibody dependent haemolysin, complement and opsonin in sera of a major carp, Cirrhina mrigala and catfish, Clarias batrachus and Heteropneustes fossilis. Comparative Immunology, Microbiology and Infectious Diseases, 1993, 16, 323-330.	1.6	15
63	Natural serum haemagglutinins (lectins) in fish: Physicochemical characterisation. Fish and Shellfish Immunology, 1993, 3, 345-360.	3.6	4
64	Identification of multiple sites of interaction between heparin and the complement system. Molecular Immunology, 1993, 30, 679-684.	2.2	88
65	Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes in vitro. International Journal of Immunopharmacology, 1992, 14, 269-273.	1.1	10
66	In vivo effects of anti-leprosy drugs on the rat peritoneal macrophages and lymphocyte subpopulations. International Journal of Immunopharmacology, 1992, 14, 721-730.	1.1	4
67	Effect of anti-leprosy drugs on superoxide anion production by rat peritoneal macrophage with special reference to light exposed clofazimine. International Journal of Immunopharmacology, 1991, 13, 419-428.	1.1	9
68	Interaction of anti-leprosy drugs with the rat serum complement system. Immunopharmacology, 1988, 15, 143-150.	2.0	10
69	Undernutrition and Altered T-cell Homeostasis in Children with Severe Chest Diseases. Journal of Tropical Pediatrics, 1988, 34, 282-288.	1.5	3
70	Complement Inhibitors Targeting C3, C4, and C5. , 0, , 75-112.		10